Lianfa Shi

Title: Innovations of Lianfa Shi in Antibody-Based Treatments

Introduction

Lianfa Shi is an accomplished inventor based in Baltimore, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel antibody-based binding agents. His work focuses on addressing critical health issues, including infections caused by toxins.

Latest Patents

Lianfa Shi holds a patent for "Tetra-specific, octameric binding agents and antibodies against toxin A and toxin B for treatment of infection." This innovative patent describes antibody-based binding agents derived from human and camelid immunoglobulins. These binding agents are designed to recognize and bind specifically to toxin A and/or toxin B, exhibiting toxin-neutralizing activity. They can be utilized to treat or prevent primary and recurrent Clostridium difficile infections (CDI). The binding agents include camelid VH peptide monomers, linked groups of VH peptide monomers, VH peptide monomers joined to antibody Fc domains, and VH peptide monomers joined to IgG antibodies.

Career Highlights

Lianfa Shi is affiliated with the University System of Maryland, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on public health and treatment methodologies.

Collaborations

Lianfa Shi collaborates with notable colleagues, including Hanping Feng and Yongjun Guan. Their combined expertise contributes to the advancement of research in the field of antibody-based therapies.

Conclusion

Lianfa Shi's innovative work in developing antibody-based binding agents represents a significant advancement in the treatment of toxin-related infections. His contributions to biotechnology continue to pave the way for new therapeutic options.